Galida - Dual PPAR Agonist for Type 2 Diabetes and Metabolic Syndrome

Print-Icon
Print

Figures from the American Heart Association suggest 20% to 25% of US adults have metabolic syndrome.
 
«Back | Next»

Return to Project




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development